SUPNSupernus Pharmaceuticals, Inc.
$42.68-7.3% 1Y
$42.68
$41.3152 weeks$57.00
The financials
Supernus Pharmaceuticals, Inc. by the numbers
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $219M in Q2 2026 (quarter ended Jun 30, 2026), up 32% from the same quarter a year earlier. That came with a gross margin of 85% and net loss of $58M. For the full year FY2025, revenue was $719M (+8.6% year on year) and net income −$39M. Its largest product in Q2 2026 was Qelbree at $89M, 41% of the disclosed total, well ahead of GOCOVRI at 17%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $219M | $165M | +32% |
| Gross profit | $185M | $149M | +25% |
| Operating income | −$58M | $12M | to a loss |
| Net income | −$58M | $22M | to a loss |
| Diluted EPS | −$1.01 | $0.40 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Qelbree | $89M | 41% |
| GOCOVRI | $38M | 17% |
| Collaboration | $35M | 16% |
| Royalty License And Other | $18M | 8.2% |
| ONAPGO | $14M | 6.2% |
| Oxtellar XR | $8.8M | 4.0% |
| Trokendi Xr | $8.4M | 3.8% |
| APOKYN | $6.3M | 2.9% |
| Manufactured Product Other | $1.9M | 0.9% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $219.1M (+5.5%)
ONAPGO grew +745% year on yearManufactured Product Other -71% year on year
Segment Latestquarter on quarteryear on year
- Qelbree$89.2M$89.2Mquarter on quarter +15%year on year +15%+15%+15%
- GOCOVRI$37.5M$37.5Mquarter on quarter +6.5%year on year +2.4%+6.5%+2.4%
- Collaboration$35.4M$35.4Mquarter on quarter +28%year on year n/a+28%n/a
- Royalty License And Other$18.0M$18.0Mquarter on quarter -39%year on year +141%-39%+141%
- ONAPGO$13.5M$13.5Mquarter on quarter +62%year on year +745%+62%+745%
- Oxtellar XR$8.8M$8.8Mquarter on quarter +18%year on year -25%+18%-25%
- Trokendi Xr$8.4M$8.4Mquarter on quarter -11%year on year -25%-11%-25%
- APOKYN$6.3M$6.3Mquarter on quarter -18%year on year -51%-18%-51%
- Manufactured Product Other$1.9M$1.9Mquarter on quarter -60%year on year -71%-60%-71%
Drug Manufacturers, Specialty & Generic
Ranks #21 of 41 by RyuScore